Insulin pump therapy for type 2 diabetes

被引：4

作者：

Susan E. Kirk

机构：

[1] Int. Medicine/Obstetrics/Gynecology, Division of Endocrinology/Metabolism, University of Virginia Health System, Charlottesville, VA 22908

来源：

Current Diabetes Reports | 2003年 / 3卷 / 5期

关键词：

Glycemic Control; Gliclazide; Insulin Lispro; Continuous Subcutaneous Insulin Infusion; Insulin Pump;

D O I：

10.1007/s11892-003-0080-3

中图分类号：

学科分类号：

摘要：

Insulin pump therapy, or continuous subcutaneous insulin infusion, has become an increasingly popular mode of therapy for patients with type 1 diabetes mellitus. Although the benefits of insulin pump therapy, such as less glycemic variability and a more flexible lifestyle, should be similar for patients with type 1 and type 2 diabetes mellitus, data on the use of insulin pump therapy in patients with type 2 diabetes are limited. This article reviews the basic principles of insulin pump therapy, the advantages and disadvantages encountered with its use, and the clinical situations where it may be considered for patients with type 2 diabetes. Copyright © 2003 by Current Science Inc.

引用

页码：373 / 377

页数：4

共 20 条

[1]

Diabetes Control and Complications Trial (DCCT): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus, N. Engl. J. Med., 329, pp. 977-986, (1993)

[2]

Weissberg-Benchell J., Antisdel-Lomaglio J., Seshadri R., Insulin pump therapy: A meta-analysis, Diabetes Care, 26, pp. 1079-1087, (2003)

[3]

Pickup J., Mattock M., Kerry S., Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: Meta-analysis of randomized controlled trials, BMJ, 324, pp. 705-708, (2002)

[4]

Bode B.W., Steed D.R., Davidson P.C., Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes, Diabetes Care, 19, pp. 324-327, (1996)

[5]

Kanakis S.J., Watts C., Leichter S.B., The business of insulin pumps in diabetes care: Clinical and economic considerations, Clin. Diabetes, 20, pp. 214-220, (2002)

[6]

Saudek C.D., Duckworth W.C., Giobbie-Hurder A., Et al., Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus, a randomized clinical trial, JAMA, 276, pp. 1322-1327, (1996)

[7]

Thompson J.S., Duckworth W.C., Saudek C.D., Giobbie-Hurder A., Surgical experience with implantable insulin pumps, Am. J. Surg., 176, pp. 622-626, (1998)

[8]

Duckworth W.C., Saudek C.D., Giobbie-Hurder A., Et al., The Veterans Affairs implantable insulin pump study, effect on cardiovascular risk factors, Diabetes Care, 21, pp. 1596-1602, (1998)

[9]

Della Casa L., del Rio G., Glaser B., Cerasi E., Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: Role of initial continuous subcutaneous insulin infusion-induced normoglycemia, Am. J. Med., 90, SUPPL. 6A, (1991)

[10]

Ilkova H., Glaser B., Tunckale A., Et al., Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment, Diabetes Care, 20, pp. 1353-1356, (1997)

← 1 2 →